BETA-THALASSEMIA (B-THAL) MARKET ANALYSIS

Beta-thalassemia (B-thal) Market, by Treatment (Iron Chelating Drugs, Erythroid Maturation Agents, Stem Cell Therapy, and Others), by Disease Indication (Beta Thalassemia Minor, Beta Thalassemia Intermedia, and Beta Thalassemia Major), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Nov 2021
Code : CMI4793
Pages :192
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

The strict pricing and reimbursement policies, high cost of drugs used in the treatment of beta-thalassemia are the factors that are expected to hinder growth of the global beta-thalassemia market over the forecast period.

Key Players

Major players operating in the global beta-thalassemia (B-thal) market include Celgene Corp., BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Orchard Therapeutics, Sangamo Therapeutics, CRISPR Therapeutics, DisperSol Technologies, Kiadis Pharma, Incyte Corporation, Editas Medicine, Global Blood Therapeutics, and Syros Pharmaceuticals.

Beta-thalassemia (B-thal) Market Report Snapshots